318 related articles for article (PubMed ID: 7577481)
1. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
3. The economics of lung cancer management in Canada.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
[TBL] [Abstract][Full Text] [Related]
4. Cost of combined modality interventions for stage III non-small-cell lung cancer.
Evans WK; Will BP; Berthelot JM; Earle CC
J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
6. Treatment pathways, resource use and costs in the management of small cell lung cancer.
Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B
Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of lung cancer management in South Western Sydney.
Kang S; Koh ES; Vinod SK; Jalaludin B
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
[TBL] [Abstract][Full Text] [Related]
8. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
Dudani S; Leighl NB; Ho C; Pantarotto JR; Zhu X; Zhang T; Wheatley-Price P
Lung Cancer; 2016 Apr; 94():74-80. PubMed ID: 26973210
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Evans WK
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
[TBL] [Abstract][Full Text] [Related]
10. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.
Louie AV; Rodrigues GB; Palma DA; Senan S
Oncologist; 2014 Aug; 19(8):880-5. PubMed ID: 24951606
[TBL] [Abstract][Full Text] [Related]
11. Estimates of the lifetime costs of breast cancer treatment in Canada.
Will BP; Berthelot JM; Le Petit C; Tomiak EM; Verma S; Evans WK
Eur J Cancer; 2000 Apr; 36(6):724-35. PubMed ID: 10762744
[TBL] [Abstract][Full Text] [Related]
12. Economics of the clinical management of lung cancer in France: an analysis using a Markov model.
Chouaïd C; Molinier L; Combescure C; Daurès JP; Housset B; Vergnenègre A
Br J Cancer; 2004 Jan; 90(2):397-402. PubMed ID: 14735183
[TBL] [Abstract][Full Text] [Related]
13. Lifetime costs of colon and rectal cancer management in Canada.
Maroun J; Ng E; Berthelot JM; Le Petit C; Dahrouge S; Flanagan WM; Walker H; Evans WK
Chronic Dis Can; 2003; 24(4):91-101. PubMed ID: 14733758
[TBL] [Abstract][Full Text] [Related]
14. Direct treatment costs for patients with lung cancer from first recurrence to death in france.
Braud AC; Lévy-Piedbois C; Piedbois P; Piedbois Y; Livartovski A; Le Vu B; Trédaniel J; Reboul F; Brewer Y; Talbi S; Blanchon F; Paschen B; Durand-Zaleski I
Pharmacoeconomics; 2003; 21(9):671-9. PubMed ID: 12807368
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
Mahar AL; Coburn NG; Johnson AP
Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
[TBL] [Abstract][Full Text] [Related]
17. Metastatic non-small cell lung cancer: costs associated with disease progression.
Fox KM; Brooks JM; Kim J
Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
[TBL] [Abstract][Full Text] [Related]
18. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
19. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
